AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 83 filers reported holding AMYLYX PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.49 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,665,479 | +213.3% | 200,190 | +269.0% | 0.03% | +237.5% |
| Q2 2023 | $1,170,129 | -37.7% | 54,248 | -15.2% | 0.01% | -27.3% |
| Q1 2023 | $1,877,701 | +1235.2% | 63,998 | +1581.5% | 0.01% | +1000.0% |
| Q4 2022 | $140,632 | +21.2% | 3,806 | -7.3% | 0.00% | 0.0% |
| Q3 2022 | $116,000 | -88.6% | 4,104 | -92.3% | 0.00% | -83.3% |
| Q2 2022 | $1,021,000 | +127.4% | 53,000 | +51.8% | 0.01% | +50.0% |
| Q1 2022 | $449,000 | – | 34,914 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 2,515,868 | $46,065,543 | 15.30% |
| Alpha Wave Global, LP | 853,262 | $15,623,227 | 9.88% |
| Saturn V Capital Management LP | 886,143 | $16,225,278 | 6.79% |
| Ally Bridge Group (NY) LLC | 272,690 | $4,992,954 | 5.86% |
| Altium Capital Management LP | 534,700 | $9,790,357 | 5.11% |
| Boxer Capital, LLC | 2,084,000 | $38,158,040 | 2.03% |
| Octagon Capital Advisors LP | 695,000 | $12,725,450 | 1.96% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 295,000 | $5,398,500 | 1.82% |
| Tri Locum Partners LP | 282,862 | $5,179,203 | 1.66% |
| Perceptive Advisors | 2,688,873 | $49,233,265 | 1.64% |